关注公众号
收藏产品 产品详情
分子别名（Synonym）
MS4A1, CD20, MS4A-1
表达区间及表达系统（Source）
FITC-Labeled Human CD20 Full Length Protein, His Tag (CD0-HF2H5) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
Predicted N-terminus: Met 1
Request for sequence蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.2 kDa. The protein migrates as 26 kDa, 40 kDa and 70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by an amphipathic scaffold coat that confers enhanced stability and a narrow particle size distribution.
The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein upon removal of the detergent.
偶联（Conjugate）
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
标记（Labeling）
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
纯度（Purity）
>85% as determined by SDS-PAGE.
制剂（Formulation）
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
质量管理控制体系（QMS）
- *The isotype control of empty/mock nanodisc (Cat. No. APO-H51H3) is sold separately and not included in protein, you can follow this link for product information.
推荐产品
数据展示
电泳（SDS-PAGE）
FITC-Labeled Human CD20 Full Length Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).
活性（Bioactivity）-SPR
Obinutuzumab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 23.4 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Protocol
Rituximab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 27.3 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Ofatumumab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 37.3 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
活性（Bioactivity）-FACS
Flow cytometric analysis of Anti-CD20 CAR-293 cells staining with FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) at 1 μg/mL (1 μg/mL corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with negative control protein. FITC signal was used to evaluate the binding activity (QC tested).
Protocol
CAR阳性表达率检测（Evaluation of CAR expression）
FACS Analysis of Non-specific binding to PBMCs
Non-specificity of FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) binding to CD3+ cells present in human PBMC. 5e5 of human PBMCs were simultaneously stained with PE-labeled anti-CD3 antibody and FITC-Labeled Human CD20 Full Length Protein, His Tag (1 μg/mL corresponds to labeling of 5e5 cells in a final volume of 100 µL) and washed and then analyzed with FACS. Both FITC and PE positive signals was used to evaluate the non-specific binding activity to human CD3+ cells (QC tested).
用户评价 发表评论
药物研发进展 
联系我们 
项目合作 